About Script Sermorelin

What Script Sermorelin is

Script Sermorelin lays the sermorelin and GHRH(1-29) literature out as a board of cited panels — one finding to a panel, the study attached, the number in place. It is a reference, not a service. No clinic sits behind the console, no pharmacy, no dispensary; the site makes nothing and sells nothing. It returns no diagnosis, no dosing, no prescriptions, and staffs no clinicians. Every panel is a summary of published science you can verify against its source, not a pitch you have to trust.

The aim is a record laid out like a developer-tool reference board: each result in its own cell, legible at a glance, and traceable to the paper that produced it.

About the name

The "script" in the domain is editorial framing, not a service. It signals the page's register — the prescribing-and-availability angle, the fact that sermorelin was once a prescription drug and is now a compounded substance — and it positions this publisher as a reader of that record. It is not a claim that the site writes prescriptions, fills scripts, dispenses anything, or connects anyone to a pharmacy. There is no clinic behind the console. The site sells nothing and offers no consultation.

How we handle evidence

Every quantitative statement on this site — a dose, a half-life, a percentage, a trial outcome — maps to a numbered citation on the full reference list, drawn from PubMed-indexed journals, controlled trials, and FDA references. We distinguish what the trials established (the pediatric height-velocity acceleration ^[1], the GH/IGF-1 reversal in older men ^[2], the pharmacokinetics ^[3]) from what remains open (long-term adult efficacy, which an Annals editorial judged not yet established ^[5]).

We are deliberate about the cognition lens: most of that evidence uses related analogs such as tesamorelin rather than sermorelin itself ^[6], and we say so wherever the topic appears. And we keep the regulatory history accurate — formerly FDA-approved for pediatric GH deficiency, withdrawn in 2008 for commercial reasons, now compounded under Section 503A ^[15] — because that history is so often misstated.

What this site is not

This is not medical advice, and nothing here is a recommendation to use sermorelin. The doses described are the doses studies administered to specific populations, reported as data. The material the literature concerns is research-grade GHRH(1-29) supplied for laboratory work, not a finished medicine or a compounded prescription. If you are weighing any health decision, that belongs with a qualified professional, not a research digest.